Market news

Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected

Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.

By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Alignment Reached with FDA on Potential Registrational Pathway in CRC On August 18, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced it had received written feedback from the FDA regarding the potential expansion of the ongoing REO 033 trial into a pivotal Part B study. REO 033 is a randomized study

Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.

Announces it has received written feedback from the U.S. Food and Drug Administration regarding the ...

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company develo

What Oncolytics Biotech's Recent Clinical Data Suggests About the Evolution of Cancer ImmunotherapyFor years, biotech investors have often evaluated oncology companies through familiar milestones, including tumor response rates, progression-free surv...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics’ regulatory momentum and continues to advance the Company’s path toward registration SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunot

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Seeking Alignment on Turning REO 033 Into a Registration-Directed Trial On July 13, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) provided a regulatory update for REO 033, an ongoing randomized study evaluating pelareorep, the company’s lead development product, in combination with folinic acid, fluorouracil, and

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design Part B will be a randomized study designed to support potential accelerated and full approval SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”

Stock Gains on Regulatory DevelopmentOncolytics Biotech Inc. (NASDAQ:ONCY) shares rose 5.